COVID-19 Vaccine Found Very Effective in Teenagers

Novavax Inc. today announced the full results from the pediatric expansion of the Phase 3 PREVENT-19 clinical trial were published in the Journal of the American Medical Association Network Open on April 26, 2027.

The study's expansion evaluated the safety and effectiveness of Novavax's COVID-19 prototype vaccine (NVX-CoV2373) in adolescents aged 12 through 17 across the U.S.

Novavax's U.S. Food and Drug Administration-approved vaccine achieved its primary effectiveness and efficacy endpoint in the trial when the Delta variant was the predominant circulating SARS-CoV-2 coronavirus strain. 

There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents.

Non-inferior neutralizing antibody responses compared to young adults in the main adult study were demonstrated, which was the critical regulatory endpoint for authorization.

And safety data showed the vaccine to be generally well-tolerated in the placebo-controlled portion of the study.

As of April 27, 2023, Novavax protein-based COVID-19 vaccines have been authorized in more than 30 markets worldwide, known as Nuvaxovid™, CovoVax™, and NVX-CoV2373.